BioRestorative Therapies, Inc. (BRTX) Financial Ratios
15 years of historical data (2010–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.20
↓-75% vs avg
5yr avg: 0.81
30Y Low0.2·High1.3
ROE
↑
-96.9%
↓+46% vs avg
5yr avg: -179.9%
30Y Low-437%·High-83%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BRTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioRestorative Therapies, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $11M | $7M | $10M | $5M | $11M | $111380 | $11M | $23M | $15M | $14M |
| Enterprise Value | $1M | $11M | $7M | $9M | $-15201231 | $13M | $8M | $15M | $26M | $18M | $15M |
| P/E Ratio → | -0.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.48 | 27.69 | 50.34 | 83.05 | 112.06 | 141.48 | 0.86 | 95.09 | 279.19 | 426.26 | 22.35 |
| P/B Ratio | 0.20 | 1.30 | 0.73 | 0.97 | 0.24 | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BRTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 26.32 | 45.39 | 71.26 | -330.46 | 163.91 | 61.14 | 131.42 | 318.82 | 484.71 | 24.18 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BRTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioRestorative Therapies, Inc. earns an operating margin of -2881.6%. Operating margins have expanded from -15838.1% to -2881.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -96.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.0% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -220.1% | 99.7% | 58.4% |
| Operating Margin | -2881.6% | -2881.6% | -10439.5% | -15838.1% | -57191.0% | -3574.1% | -6486.2% | -6889.8% | -10338.6% | -21447.6% | -1140.1% |
| Net Profit Margin | -2239.2% | -2239.2% | -7145.2% | -11037.0% | -96311.5% | -14639.9% | -11267.6% | -11277.3% | -11660.1% | -23755.4% | -1259.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -96.9% | -96.9% | -102.7% | -82.9% | -437.2% | — | — | — | — | — | — |
| ROA | -72.1% | -72.1% | -71.7% | -68.0% | -330.6% | -387.8% | -1101.9% | -848.4% | -565.8% | -480.2% | -427.3% |
| ROIC | -100.4% | -100.4% | -125.7% | -281.3% | -2410.7% | — | — | — | — | — | — |
| ROCE | -124.7% | -124.7% | -148.8% | -116.6% | -207.2% | -83.3% | — | — | — | — | — |
BRTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $547890 exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.02 | 0.03 | 0.03 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | -0.07 | -0.14 | -0.94 | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -14.49 | -1.68 | -1.64 | -2.37 | -7.70 | -10.21 | -11.89 |
Net cash position: cash ($547890) exceeds total debt ($0)
BRTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BioRestorative Therapies, Inc.'s current ratio of 2.97x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.53x to 2.97x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.97 | 2.97 | 4.37 | 2.53 | 59.01 | 3.05 | 0.01 | 0.02 | 0.06 | 0.01 | 0.05 |
| Quick Ratio | 2.97 | 2.97 | 4.37 | 2.53 | 59.01 | 3.05 | 0.01 | 0.02 | 0.06 | 0.01 | 0.05 |
| Cash Ratio | 2.86 | 2.86 | 4.24 | 2.47 | 57.79 | 2.93 | 0.00 | 0.01 | 0.05 | 0.01 | 0.03 |
| Asset Turnover | — | 0.03 | 0.01 | 0.01 | 0.00 | 0.02 | 0.09 | 0.09 | 0.05 | 0.02 | 0.31 |
| Inventory Turnover | 109.94 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 171.49 | 48.32 | 48.75 | 39.67 | 80.58 | 89.85 | 95.36 | 171.23 | 60.24 | 54.19 |
BRTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioRestorative Therapies, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $4M | $4M | $1M | $394704 | $5569 | $2932 | $1528 | $1174 | $827 |
Peer Comparison
Compare BRTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BRTXYou | $2M | -0.2 | — | — | 93.0% | -2881.6% | -96.9% | -100.4% | — |
 MESO | $2B | -17.6 | — | — | 70.2% | -363.1% | -19.0% | -8.5% | — |
 XTNT | $80M | -4.8 | — | — | 58.2% | -10.3% | -34.9% | -12.8% | — |
 MDXG | $548M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 RGEN | $7B | 147.0 | 52.4 | 75.9 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 CYTK | $9B | -11.4 | — | — | 88.5% | -695.4% | — | -305.3% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CELH | $9B | 137.0 | 18.2 | 27.2 | 50.4% | 18.6% | 5.2% | 19.7% | 1.3 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 BIO | $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See BRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BRTX vs MESO
Side-by-side business, growth, and profitability comparison vs Mesoblast Limited.
Start ComparisonBRTX — Frequently Asked Questions
Quick answers to the most common questions about buying BRTX stock.
What is BioRestorative Therapies, Inc.'s P/E ratio?
BioRestorative Therapies, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is BioRestorative Therapies, Inc.'s ROE?
BioRestorative Therapies, Inc.'s return on equity (ROE) is -96.9%. The historical average is -179.9%.
Is BRTX stock overvalued?
Based on historical data, BioRestorative Therapies, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BioRestorative Therapies, Inc.'s profit margins?
BioRestorative Therapies, Inc. has 93.0% gross margin and -2881.6% operating margin.